| Mrs Maryjo Ference, OD | |
|
2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302-0951 | |
| (248) 258-9000 | |
| (248) 499-6372 |
| Full Name | Mrs Maryjo Ference |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 34 Years |
| Location | 2550 S Telegraph Rd Ste 100, Bloomfield Hills, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073734224 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152WP0200X | Optometrist - Pediatrics | 4901003317 (Michigan) | Primary |
| 152W00000X | Optometrist | 4901003317 (Michigan) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vision Specialists Of Birmingham, Pllc | 0244209468 | 6 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
| Provider Name | Vision Specialists Of Birmingham, Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1356488597 PECOS PAC ID: 0244209468 Enrollment ID: O20040924000916 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
| Provider Name | Visionworks Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1366822991 PECOS PAC ID: 4385639616 Enrollment ID: O20151002002485 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
| Provider Name | West Point Optical Group |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1831548890 PECOS PAC ID: 9032491246 Enrollment ID: O20170124001437 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
| Provider Name | Myeyedr Optometry Of Michigan, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1639723596 PECOS PAC ID: 7416288949 Enrollment ID: O20191014002048 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Maryjo Ference, OD 2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302-0951 Ph: (248) 258-9000 | Mrs Maryjo Ference, OD 2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302-0951 Ph: (248) 258-9000 |
News Archive
A first participant was dosed at I-Motion, the pediatric clinical trial platform for neuromuscular diseases located at Trousseau hospital in Paris, as part of the gene therapy trial in Duchenne muscular dystrophy (DMD) conducted by Genethon.
For the first time, scientists from the University of Washington School of Medicine, Indiana University Bloomington and the University of Cambridge have determined how a plant hormone - auxin - interacts with its hormone receptor, called TIR1.
Uroplasty, Inc. (AMEX: UPI), a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today announced that nine abstracts outlining study results submitted by various researchers have been accepted for presentation at the 2010 Annual Meeting of the Society for Urodynamics and Female Urology (SUFU), February 23-27, 2010 in St. Petersburg, FL. Presentations accepted were for both Uroplasty's Urgent® PC Neuromodulation System and Macroplastique® urethral bulking agent products.
Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.
› Verified 9 days ago
Dr. Paul Charles Feinberg, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2550 S Telegraph Rd Ste 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-6372 | |
Dr. Debra Lynn Feinberg, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2550 S Telegraph Rd, Suite 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-6372 | |
Eliza Seros, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 4114 W Maple Rd, Bloomfield Hills, MI 48301 Phone: 248-539-4800 | |
Dr. Michael S Weishaus, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 6523 Telegraph Rd, Bloomfield Hills, MI 48301 Phone: 248-593-9955 Fax: 248-593-9966 | |
Vision Specialists Of Michigan Optometrist Medicare: Medicare Enrolled Practice Location: 2550 S Telegraph Rd, Suite 100, Bloomfield Hills, MI 48302 Phone: 248-258-9000 Fax: 248-499-7362 | |
Dr. Kevin Semma, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 3683 W Maple Rd, Bloomfield Hills, MI 48301 Phone: 248-246-4466 |